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Pituitary hormone deficiencies, with Growth Hor-
mone deficiency being most frequent (1 in 3,500-
10,000 births), cause significant morbidity. Regener-
ationofmissingendocrine cellswouldbeasignificant
improvement over hormone replacement therapies,
which incur side effects and do not mimic physiolog-
ical secretion patterns. Recent in vitro studies have
identified a population of adult pituitary progenitors
that express the HMG box transcription factors
SOX2 and SOX9. Here, we apply cell-lineage tracing
analysis to demonstrate that SOX2- and SOX9-ex-
pressing progenitors can self-renew and give rise to
endocrine cells in vivo, suggesting that theyare tissue
stem cells. Moreover, we show that they can become
mobilized and differentiate into the appropriate
endocrine cell types in response to physiological
stress. Our results highlight the pituitary as a model
for exploring how physiological changes influence
stem cell behavior and suggest that manipulation of
endogenous pituitary stem cells is a potential thera-
peutic strategy for pituitary deficiencies.
INTRODUCTION
Throughout the life of an animal, organ-specific differentiated
cell types are renewed. This can be achieved by cell division,
as shown by hepatocytes in the liver, and/or by differentiation
from a pool of undifferentiated multipotent progenitors or stem
cells, such as the gastrointestinal epithelium. While adult pro-
genitors or stem cells are being found in an increasing number
of organs, their participation in tissue homeostasis varies ac-
cording to rates of cell turnover and the ability of differentiated
cell types to self-renew. One central goal of regenerative medi-
cine is to be able to instruct resident tissue stem cells to repair
a deficient organ. It is therefore crucial to know how organ-
specific tissue stem cells function under normal physiological
situations and also whether it is possible to stimulate their
regenerative potential.CeThe pituitary is an endocrine gland involved in maintaining
body homeostasis and controlling physiological processes
such as reproductive maturation and function. It does so by
secreting hormones under control of the hypothalamus, which
acts to centralize peripheral information. The pituitary is an organ
with a low cell turnover where differentiated endocrine cells are
able to divide, but they do so rarely (Levy, 2002). Physiological
situations evolve during life: growth is crucial in juvenile animals,
later, sexual maturation occurs, and, in the female, pregnancy
and lactation can take place. All these processes are controlled
by specific hormonal outputs from the pituitary, which must
constantly modulate its hormonal secretions appropriately.
This adaptability can be achieved in different ways, such as by
modifying levels and/or temporal patterns of hormonal synthesis
and secretion, but it has also been proposed that a population of
adult progenitor/stem cells is involved. Recently, several labs
have characterized (likely overlapping) populations of such cells
(for review see Rizzoti, 2010). The ability to control the activity of
these progenitors in vivo, or to use them in regenerative or cell
transplant therapies, could be used to manipulate physiological
states or to treat congenital or acquired pituitary hormone
deficiencies, which are associated with significant morbidity.
This could also alleviate both the side-effects and cost of current
hormone replacement and substitution therapies (for review see
Castinetti et al., 2011).
We showed that pituitary progenitors express the SRY-related
HMG box transcription factors SOX2 and SOX9 (Fauquier et al.,
2008). These belong to different subfamilies, SOXB1 and SOXE,
and are therefore likely to regulate different sets of target genes.
Both proteins have pleiotropic roles during organogenesis but
also in different adult stem cell populations (for review see Sarkar
and Hochedlinger, 2013). During pituitary development, SOX2 is
expressed initially in all cells of Rathke’s Pouch (RP), an outpock-
eting of the oral ectoderm that gives rise to the anterior and inter-
mediate pituitary (Fauquier et al., 2008), where it is required for
progenitor proliferation (Jayakody et al., 2012 and our unpub-
lished data), while SOX9 is expressed later, after the first and
main wave of embryonic progenitor cell cycle exit (Davis et al.,
2011; Fauquier et al., 2008). Expression of both proteins is down-
regulated upon endocrine differentiation. This pattern is still pre-
sent in the adult where SOX2;SOX9-double-positive cells form
the epithelium lining the pituitary cleft, the remnant of RP lumen,
proposed as a pituitary stem cell niche, and are also scattered inll Stem Cell 13, 419–432, October 3, 2013 ª2013 The Authors 419
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pituitary spheres initially express SOX2, then SOX9, and can
give rise to endocrine cells (Fauquier et al., 2008). In vivo, it
has been suggested that SOX2+ve cells could generate new
endocrine cells in experimental endocrine cell elimination
models, where limited regeneration was observed (Fu et al.,
2012; Fu and Vankelecom, 2012), although these studies were
correlative and did not involve fate-mapping.
In this study, we demonstrate that SOX2- and SOX9-positive
progenitors are the sphere-forming cells in vitro and, from line-
age analysis, demonstrate that they give rise to endocrine
cells in vivo, both in the embryo and postnatally. Long-term
maintenance of progenitor identity suggests that SOX2- and
SOX9-expressing cells are tissue stem cells, although these
give rise to differentiated progeny infrequently in unchal-
lenged adult animals. However, in situations where the
pituitary is known to show plasticity, we show that adult pitui-
tary stem cells can make a significant contribution to the
pool of new endocrine cells generated in response to physio-
logical demand. This represents a first step toward the use of
pituitary stem cells to modulate endocrine output and treat
deficits.
RESULTS
SOX2- and SOX9-Positive Cells Are the
Pituisphere-Forming Cells
We initially checked that the targeted alleles Sox2EGFP and
Sox9iresGFP recapitulated SOX2 and SOX9 expression patterns,
respectively, in the pituitary (Figures 1A and 1B). We isolated
SOX2-positive cells by FACS after dissociation of pituitaries
from Sox2EGFP/+ mice (Ellis et al., 2004) (Figure 1C). We plated
the EGFP-positive fraction and, in parallel, an equivalent number
of pituitary EGFP-negative cells in sphere forming conditions.
After 1 week in culture, only the EGFP-positive, SOX2-positive
fraction contained pituispheres from which hormone-positive
endocrine cells could be further differentiated (Figure 1G) (Ando-
niadou et al., 2012). We also isolated SOX9-positive cells using
Sox9iresGFP/iresGFP mice (Figure 1D) (Furuyama et al., 2011).
Upon being plated, the GFP-positive fraction contained pitui-
spheres that gave rise to endocrine cells (Figure 1F). A very small
number of GFP+ve spheres was observed when the entire
GFP-negative fraction was plated from either Sox2EGFP/+ or
Sox9iresGFP/iresGFP mice (0.0035%, n = 2). It is most likely that
these originate from cells that were not sorted appropriately.
However, as we proposed previously, the spheres in the latter
could come from SOX2+ve;SOX9ve cells (Fauquier et al., 2008).
Similarly the spheres in the SOX2-EGFPve fraction could come
from SOX9+ve;SOX2ve cells (Figure S1 available online). Our
previous results (Fauquier et al., 2008) showed that SOX9 only
appeared after a few days in sphere cultures. This is in apparent
contrast with the sphere-forming ability of the SOX9-IRES-GFP-
positive fraction. We therefore further examined spheres derived
from the latter, finding that SOX9 was downregulated, while
GFP persists during early sphere formation, only to resume after
6–7 days (Figure S1). In conclusion, both SOX2- and SOX9-
positive cells from the adult pituitary have sphere-forming ability,
but during their initial formation the expression of the twoproteins
appears to recapitulate their embryonic pattern.420 Cell Stem Cell 13, 419–432, October 3, 2013 ª2013 The AuthorsSOX2- and SOX9-Positive Cells Generate Endocrine
Cells in the Embryonic Pituitary
During embryogenesis, SOX2 is expressed throughout RP at
least from 10.5 days post coitum (dpc), while SOX9 starts to
be faintly expressed in a few cells at 12.5 dpc and is then upre-
gulated from 14.5 dpc until adulthood, when both proteins
clearly colocalize (Figure S2 and Fauquier et al., 2008). In order
to investigate the differentiation potential of these progen-
itors in vivo, we used Sox2CreERT2 (Arnold et al., 2011) and
Sox9ires-CreERT2 alleles (Furuyama et al., 2011). These were
bred into mice carrying the Cre-reporter R26REYFP. Cre activity
was induced with 4-hydroxy-tamoxifen (4-OHT) in embryos at
several stages and pituitaries harvested at 18.5 dpc, toward
the end of gestation.
When we induce Cre activity at 9.5 and 10.5 dpc or 11.5 and
12.5 dpc in Sox2CreERT2/+;R26REYFP/+ embryos, before or at the
start of endocrine differentiation (Davis et al., 2011), we observe
EYFP-positive cells in all endocrine lineages at the end of gesta-
tion (Figures 2A–2F). More precisely, when induction is per-
formed at 11.5 and 12.5 dpc, 56%of EYFP+ve cells in the anterior
lobe (excluding those in the cleft) are Pit-1 positive (representing
somatrotrophs, lactotrophs, and thyrotrophs and their immedi-
ate progenitors), while 9% are adrenocorticotropic hormone
(ACTH) positive corticotrophs (Figure 2F, Table 1, and Table
S1). We also observe luteinizing hormone (LH)- and follicle-stim-
ulating hormone (FSH)-positive gonadotrophs within the SOX2
lineage, but because gonadotroph repartition is not homoge-
nous in the gland (Budry et al., 2011), we cannot count the pro-
portion of EYFP+ve cells that become gonadotrophs. Some
EYFP+ve cells express SOX2 (16%, in the anterior lobe); more-
over, the cleft also contains a significant proportion of EYFP+ve
cells (but note that these are not included in the quantitative
analysis). These cells are all hormone-negative, showing that
not all progenitors differentiate and/or reflecting symmetric or
asymmetric self-renewal divisions (Figure 2F). About 20% of
EYFP-positive cells did not costain with Pit-1, ACTH, or SOX2.
These are likely to be differentiating progenitors (for the gonado-
troph and corticotroph lineages), gonadotrophs, and probably
Pit-1-independent thyrotrophs.
We next used the Sox9ires-CreERT2/+ animals and noticed an
obvious reduction in recombination efficiency compared
to Sox2CreERT2 (Figure S2). While it is clear that there are
many more SOX2- than SOX9-positive cells at early stages
(12.5 dpc), even when induction is performed later (13.5 dpc),
when both proteins are coexpressed, or in the adult (see below),
Sox2-CreERT2 is more efficient. This may reflect low expression
levels of SOX9 compared to SOX2 in the pituitary or a difference
in expression or activity of the CreERT2 cassette. Moreover,
because CreERT2 replaces the SOX2 open reading frame
(ORF) in Sox2CreERT2/+ animals (Arnold et al., 2011), one copy
of Sox2 is missing. This is known to affect pituitary development
and function (Kelberman et al., 2006). Although the phenotype is
mild and affects all hormonal cell types, this may also account for
some quantitative differences seen between the two Cre drivers.
In contrast, CreERT2 was inserted following an IRES into the
Sox9 30UTR because SOX9 heterozygosity is lethal (Soeda
et al., 2010). Translation following an IRES is often less efficient
compared to that initiated from the endogenous transcript.
Nevertheless, the lower recombination efficiency is beneficial
Figure 1. SOX2- and SOX9-Positive Cells Are the Sphere-Forming Cells
(A and B) SOX2-EGFP and SOX9-IRES-GFP alleles faithfully recapitulate SOX2 (A) and SOX9 (B) expression in the pituitary. Note that SOX2-EGFP is not present
in cells where SOX2 staining is cytoplasmic (arrows).
(C and D) FAC sorting of 3 week-old Sox2EGFP/+ and 4-week-old Sox9iresGFP/iresGFP.
(E and F) Spheres are observed in SOX2-EGFP and SOX9-IRES-GFP-positive fractions (bright field and live fluorescence).
(G and H) Spheres obtained from SOX2-positive cells (G, DAPI and immunofluorescence for GFP and anterior pituitary hormones) and SOX9-positive cells
(H, DAPI and immunofluorescence for GFP and all anterior pituitary hormones) are able to give rise to hormonal cells in differentiating conditions.
Scale bars: 50 mm for (A) and (B) and 5 mm for (G) and (H). See also Figure S1.
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Table 1. Lineage Tracing Quantification
Number of EYFP+ve
Cells Counted
EYFP;*SOX
(Percent) EYFP;Pit-1 (Percent) EYFP;ACTH (Percent)
Embryonic
lineage
tracing
SOX2-CreERT2, induced
at 11.5 and 12.5 dpc,
harvested 18.5 dpc
2426, n = 3 16, SD = 1.7 55.4, SD = 9.6 9.3, SD = 2.9
SOX2-CreERT2, induced
at 13.5 dpc, harvested
18.5 dpc
684, n = 4 37, SD = 10
EYFP;Pit-1-ACTH
(Percent)
SOX9-CreERT2, induced
at 11.5 and 12.5 dpc,
harvested 18.5 dpc
677, n = 7 37, SD = 9.6 41.4, SD = 3.8
EYFP;LH
(Percent)
EYFP;ACTH
(Percent)
EYFP;PRL
(Percent)
Postnatal
lineage
tracing
SOX2-CreERT2, induced
at P0/P2, harvested at
4 weeks
4106, n = 4 35, SD = 3.2 39, SD = 5.6 3.2, SD = 0.7 0.9, SD = 1.2
SOX2-CreERT2, induced
at P0/P2, harvested at
8 weeks
987, n = 2 42, SD = 2.5 6.7, SD = 0.2
SOX9-CreERT2, induced
at P0/P2, harvested at
4 weeks
1897, n = 8 49, SD = 8.4 34, SD = 4.3 0.9 (n = 1) 7, SD = 7.3
EYFP;SOX9;SOX2+ve
(Percent) within
EYFP;SOX9
EYFP;SOX9;SOX2ve
(Percent) within
EYFP;SOX9
EYFP;Pit-1
(Percent)
Adult
lineage
tracing
SOX9-CreERT2, induced
at 8 weeks, harvested at
6 to 12 months
436, n = 5 87, SD = 9.8 99, SD = 0.2 (n = 2) 1.15, SD = 0.2 (n = 2) 2 (n = 1)
Double or triple immunofluorescence was performed for EYFP and progenitor or endocrine markers. EYFP+ve cells were counted in an average of 10
fields taken across the entire pituitary for each staining. Percentage of EYFP;marker+ve/EYFP+ve was calculated. Numbers are given when fewer than
three pituitaries were used for a single staining. *SOX = SOX2 for Sox2CreERT2 samples and SOX9 for Sox9ires-CreERT2. See also Table S1.
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ideal tool to perform lineage tracing in the pituitary.
When we induce Cre activity in Sox9ires-CreERT2/+;R26REYFP/+
embryos at 11.5 and 12.5 dpc, we also observe EYFP-positive
cells in all lineages (Figures 2G–2L, Table 1, and Table S1).
More precisely, we mainly observe EYFP-positive cells in the
Pit-1 lineage and in some rare corticotrophs (together represent-
ing 41% of the EYFP+ve cells). We very rarely observe EYFP+ve
gonadotrophs. This is likely explained by both the lower recom-
bination efficiency and the fact that LH- and FSH-positive cellsFigure 2. SOX2- and SOX9-Positive Progenitors Give Rise to Endocrin
Progenitors in the Adult
(A–F) Sox2CreERT2 embryonic lineage tracing.
(G–L) Sox9ires-CreERT2 embryonic lineage tracing. 4-OHT (0.1 to 0.15 mg/g/day) w
18.5 dpc and immunofluorescence was performed for GFP, SOX2, SOX9, and ant
progenitors, ACTH for corticotrophs, and LH and FSH for gonadotrophs). (L) D
‘‘Other’’ refers to the proportion of EYFP+ve cells that were not identified.
(M) Proportions of SOX+ve progenitors stained at 18.5 dpc after induction of S
upregulated (13.5 dpc), along with Sox9ires-CreERT2 results. Data are presented as
(N) Model recapitulating results from the embryonic lineage tracings according t
(O and P) Fetal SOX2- (O) and SOX9- (P) positive progenitors give rise to adult
(Sox9ires-CreERT2) and 13.5 dpc (Sox2CreERT2). Pituitaries were harvested postnata
positive progenitors. Insets show SOX2 and SOX9 staining in triple-positive cells
Scale bars: 10 mm for all panels. See also Table S1.
Cerepresent a relatively small population. Finally, a significant per-
centage of EYFP+ve cells still express SOX9 at 18.5 dpc (36%).
Again a proportion of cells (about 20%) are not costained by
Pit-1, ACTH, or SOX9.
Comparing the two lineage tracing methods, there is a signif-
icant reduction in differentiated progeny when using Sox9 rather
than Sox2 to drive CreERT2 (41.4% versus 64.7% Pit-1/ACTH
cells) and a corresponding increase in progenitors (36.8%versus
16%, respectively). It is very likely that EYFP+ve cells observed
with the former are induced later than with the latter, as SOX2e Cells in the Embryo and to SOX2;SOX9-Double-Positive Putative
as given to pregnant females at 11 and 12.5 dpc. Pituitaries were harvested at
erior pituitary cell lineages (Pit-1 for GH, PRL, and TSH-secreting cells and their
ouble-positive cells were counted for each lineage in at least three embryos.
ox2CreERT2 early, before SOX9 is expressed (11.5+12.5), or late, as SOX9 is
mean ± SEM.
o expression timing of SOX2, SOX9, and Cre induction.
progenitors. 4-OHT (0.1 to 0.15 mg/g) was given to pregnant females at 11.5
lly at 8 weeks. EYFP expression was observed in particular in SOX2/9-double-
.
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sion only becomes significant at 14.5 dpc. Progenitor cell cycle
exit in the pituitary has been shown to occur for all endocrine
populations mainly between 11.5 and 13.5 dpc (Davis et al.,
2011). Therefore lineage tracing performed at the end, and/or
after this phase, as would happen with Sox9ires-CreERT2, should
give rise to fewer differentiated progeny, and, in consequence,
increased retention of the lineagemarker in progenitors. To verify
this hypothesis, we gave 4-OHT to Sox2CreERT2/+;R26REYFP/+
embryos at 13.5 dpc, and observed a higher percentage of
EYFP;SOX2 double-positive cells (37%, Figure 2M, Table 1,
and Table S1), comparable to that obtained with Sox9ires-CreERT2.
Taken together, these results show that SOX2- and SOX9-
positive precursors differentiate into endocrine cells in the devel-
oping pituitary, and moreover, that they are in agreement with
birth-dating data showing that progenitors differentiate more
efficiently before 13.5 dpc (Davis et al., 2011). When Cre activity
is induced in Sox2CreERT2/+;R26REYFP/+ embryos before 13.5
dpc, at a time prior to the onset of SOX9 expression, a greater
proportion of progenitors differentiate compared to its later in-
duction, after SOX9 is upregulated andwhenCre activity can first
be induced in Sox9ires-CreERT2/+;R26REYFP/+embryos (Figure 2N).
Embryonic SOX2 and SOX9-Positive Cells Give Rise to
Adult Progenitors
It has been proposed that embryonic and adult progenitors
derive from distinct cell populations, because lineage tracing
using a NestinCre transgene only gave rise to significant endo-
crine progeny postnatally (Gleiberman et al., 2008). To test this
hypothesis, we induced Cre activity in Sox2CreERT2/+;R26REYFP/+
(13.5 dpc) and Sox9ires-CreERT2/+;R26REYFP/+ (11.5 dpc) embryos
and harvested pituitaries from newborns and adults. Most of the
labeled cell progeny had differentiated (data not shown), but we
were able to detect, in both sets of samples, EYFP;SOX2;SOX9-
triple-positive cells (Figures 2K and 2L). More precisely, in both
Sox2CreERT2/+;R26REYFP/+ (n = 2, SD = 1.5; 8 and 17 weeks)
and Sox9ires-CreERT2/+;R26REYFP/+ (n = 3, SD = 2.5; 8 to 26 weeks)
pituitaries, an average of 3% of EYFP-positive cells remained
SOX2- and SOX9-positive, respectively, in the anterior lobe
(excluding the cleft). Therefore, in agreement with recent data
for other SOX2+ve progenitors in various adult epithelial tissues
(Arnold et al., 2011), a proportion of embryonic SOX2;SOX9-
positive progenitors remain undifferentiated and maintain their
identity until adulthood.
SOX2- and SOX9-Positive Cells Give Rise to Endocrine
Cells during the Postnatal Pituitary Growth Phase
The murine pituitary is characterized by a phase of rapid growth
postnatally to reach its adult size. Differentiated endocrine cells
are known to proliferate during this phase (Kominami et al.,
2003). We decided to study the contribution of SOX2+ve and
SOX9+ve cells during this period by inducing Cre activity in
newborns and analyzing pituitaries at 4 weeks (Figure 3). As
observed in embryos, recombination is much less efficient in
Sox9ires-CreERT2/+;R26REYFP/+ versus Sox2CreERT2/+;R26REYFP/+
animals. While we routinely counted more than 200 EYFP+ve
cells/animal/hormone for Sox2CreERT2/+;R26REYFP/+ samples,
for Sox9ires-CreERT2/+;R26REYFP/+ we typically were only able to
count 50 to 100 cells (Table 1 and Table S1).424 Cell Stem Cell 13, 419–432, October 3, 2013 ª2013 The AuthorsUsingSox2CreERT2, wemainly observed colocalization of EYFP
with LH+ve (and FSH, data not shown) gonadotrophs (39%,
Table 1). ACTH+ve;EYFP+ve cells were detected at a lower fre-
quency (3.2%), and while EYFP+ve lactotrophs, somatotrophs,
and thyrotrophs were present, they were rare (<1%). A large pro-
portion of EYFP+ve cells were SOX2+ve (35%), suggesting that
they were the products of self-renewal divisions (Figures 3A–
3F). In 8-week-old animals, a similar percentage of EYFP;LH-
and EYFP;ACTH-double-positive cells are still present (Table 1
and Table S1). A proportion of EYFP+ve cells (about 20%, as esti-
mated from double staining, and confirmed in one animal by
triple EYFP;SOX2;ACTH-LH staining, data not shown) appears
to be negative for both SOX2 and LH;ACTH. These cells
comprise a small percentage of prolactin (PRL)-, thyroid-stimu-
lating hormone (TSH)-, and growth hormone (GH)-positive cells
as well as others that are presumably differentiating and not
yet expressing hormones.
Using Sox9ires-CreERT2, we also detected EYFP mainly in LH+ve
(and FSH+ve) gonadotrophs (34%) (Table 1, Table S1, and data
not shown) and in some lactotrophs. In one animal where recom-
bination was particularly efficient, we were able to detect a few
GH+ve;EYFP+ve and ACTH+ve;EYFP+ve cells. A significant per-
centage of the EYFP+ve cells still expressed SOX9 (50%), higher
than that observed with Sox2CreERT2 (Figures 3G–3L). The per-
centage of EYFP+ve gonadotrophs remained high in 8-week-
old animals (24%; n = 2, SD = 9.8, 1 female and 1 male). A
proportion of EYFP+ve cells were not identified, but these
were less frequent compared to those seen in Sox2CreERT2 line-
age tracing experiments. With triple staining (EYFP;SOX9;LH-
PRL, n = 3), about 10% of EYFP+ve cells were not identified
(Figure 3L).
We suspected that the prominent differentiation toward gona-
dotroph fate at these stages could be due to the estrogen (E2)
receptor modulator tamoxifen. We therefore counted gonado-
trophs in tamoxifen- versus oil-treated animals and observed
many more in the former (Figure S3), which provides an explana-
tion for the high percentage of LH-positive cells in the progeny
of both SOX2- and SOX9-positive progenitors.
In summary, SOX2+ve and SOX9+ve progenitors can differen-
tiate into all endocrine cell lineages postnatally. Despite the
fact that more than 95% of progenitors are SOX2;SOX9-dou-
ble-positive (Figure S1), there are two main differences between
Sox2CreERT2 and Sox9ires-CreERT2 lineage tracing experiments.
First, a greater proportion of descendants appear to lose
progenitor marker expression with Sox2CreERT2 compared to
Sox9ires-CreERT2 (65% versus 50%). Second, we observe more
corticotrophs when tracking cell fate with Sox2CreERT2 and
more lactotrophs when using Sox9ires-CreERT2 (although the
proportion of lactotrophs varied between animals; Table 1 and
Table S1). As mentioned above, there is a small proportion of
SOX2+ve;SOX9ve cells (Fauquier et al., 2008) and SOX9+ve;
SOX2ve cells. The differences seen between the two fate-map-
ping strategies could therefore reflect the progeny of these single
positive cells. Alternatively, or in addition, cell fate decisions may
be affected by Sox2 haploinsufficiency in Sox2CreERT2 animals
(Kelberman et al., 2006).
To better characterize these differences, we first
induced Cre activity in adult Sox2CreERT2/+;R26REYFP/+ and
Sox9ires-CreERT2/+;R26REYFP/+ animals and analyzed progeny
Figure 3. SOX2- and SOX9-Positive Post-
natal Progenitors Give Rise to Endocrine
Cells and Folliculo-Stellate Cells
(A–F) Sox2CreERT2 postnatal lineage tracing.
(G–L) Sox9ires-CreERT2 postnatal lineage tracing.
4-OHT (1 mg) was given to P0–P2 pups and pitui-
taries were harvested at 4 weeks.
(A–L) Immunofluorescence for EYFP, SOX2, SOX9,
and anterior pituitary hormones were then per-
formed. Double-positive cells were counted for
each lineage in at least four animals. ‘‘Other’’ refers
to the proportion of EYFP+ve cells that were not
identified. SOX2 and SOX9 progenitors participate
in pituitary growth postnatally and give rise to
differentiated cells in all endocrine lineages.
(M–O) Sox9ires-CreERT2 adult lineage tracing.
Tamoxifen (5 mg/25 g/day for 3 days) was given to
8 week-old animals. Pituitaries were harvested at
one year (M and N) or after 2 months (O). (M) Triple
SOX2;SOX9;EYFP and double (N) GH;EYFP and
(O) S100;EYFP are shown. Insets show SOX2 and
SOX9 staining in triple-positive cells.
Scale bars: 10 mm for all panels. See also Figure S3
and Table S1.
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that retain a progenitor identity. Of the EYFP+ve cells, 96%
remain SOX2;SOX9-double-positive (n = 4, SD = 1.3) in the
latter, while only 77% (n = 3, SD = 6.2) did so in the former
(**p = 0.002). GH+ve somatotrophs and ACTH+ve corticotrophs
were commonly seen among the differentiated (SOX2ve;
SOX9ve) descendants of Sox2CreERT2 progenitors, whereas cor-
ticotrophs were very rare 1 week after induction when using
Sox9ires-CreERT2 (Figure 6B). There were also more differentiated
endocrine cells in Sox2 heterozygous (Sox9iresGFP/+;
Sox2bgeo/+ and Sox2EGFP/+) versus control (Sox9iresGFP/+) pitui-Cell Stem Cell 13, 419–43spheres (33%, 14.3%, and 4.17%,
respectively). (Sox2bgeo is described in
Avilion et al., 2003.)
To determine whether Sox2 haploin-
sufficiency renders cells more prone to
differentiation, we performed lineage
tracing analysis using Sox9ires-CreERT2/+;
R26REYFP/+;Sox2bgeo/+animals. Induction
was performed shortly after birth and pitu-
itaries were harvested at 4 weeks. There
was only a slight difference in the pro-
portion of cells retaining progenitor
identity (EYFP;SOX9-double-positive) be-
tween Sox2 haploinsufficient pituitaries
(49.7%, SD = 7.2, n = 5) compared with
Sox9ires-CreERT2/+;R26REYFP/+ littermates
(53.5%, SD = 6.3, n = 5). Sox2 haploinsuf-
ficiency is therefore unlikely to explain
most of the differences we observe.
Stem cells in the CNS similarly express
both SOX2 and SOX9, but in this case
there is an obvious distinct role for the
two proteins in subsequent progenitor lin-
eages, with SOX2 remaining active in neu-roblasts and SOX9 in glial cell progenitors (Scott et al., 2010). The
use of the two Cre drivers to follow cell fates in the CNS would
therefore lead to overlapping but quite skewed distributions, as
it is not possible to limit Cre activity to just the stem cells. If similar
differences between SOX2- and SOX9-expressing cells occur in
the pituitary, these must be subtle or transient; therefore, the
results most likely reflect the difference in efficiency between
the two lineage tracing tools (see Discussion).
This is being explored further, but we decided to pursue adult
lineage tracing only using Sox9ires-CreERT2 because, in contrast
with Sox2CreERT2, both copies of the gene are present and2, October 3, 2013 ª2013 The Authors 425
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function in both mice and humans (Kelberman et al., 2006). We
had previously hypothesized that SOX9-positive cellsmay repre-
sent transit amplifying progenitors and this was based on the
absence of SOX9 protein from early spheres (Fauquier et al.,
2008). However, as we have shown here, SOX9-positive cells
can form spheres (Figure 1) and this, along with the lineage
tracing results, suggests that SOX9, like SOX2, is a bona fide
marker for adult pituitary progenitors.
SOX2- and SOX9-Positive Cells Maintain Their Identity
in Adults
To assess the potential of adult progenitors, we induced Cre
activity in 8-week-old Sox9ires-CreERT2/+;R26REYFP/+ animals
and harvested pituitaries between 6 and 12 months later. At
these stages, there are very few EYFP+ve cells and the vast
majority are double positive for SOX2 and SOX9 (Figure 3M,
Table 1, and Table S1). However, we were able to detect some
differentiated progeny (Figure 3N long-term, Figure 6B short-
term, and Figure S3). Moreover, some pituitary supporting cells,
such as S100+ve heterogenous folliculo-stellate cells, are among
the descendants of the progenitors (Figure 3P). This was ex-
pected since we had previously shown that SOX2 and S100
can colocalize (Fauquier et al., 2008).
The fact that SOX9+ve progenitors remain both SOX2- and
SOX9-positive after long-term lineage labeling strongly sug-
gests that both proteins are markers of stem cells and not
transit amplifying progenitors (for review see Grompe, 2012).
Short-term BrdU incorporation experiments show that the
SOX2+ve;SOX9+ve cells proliferate, although at a low rate,
whereas very few SOX2-positive cells were found to be BrdU
positive in label-retaining assays (Fauquier et al., 2008, and
see below). Together, these results suggest that the stem cells
self-renew, but differentiate rarely in the adult animal, at least
when these are maintained in standard conditions. Therefore
endocrine cell turnover in these circumstances may rely mostly
on differentiated cell proliferation.
We then decided to analyze the regenerative potential of the
SOX2+ve;SOX9+ve cells in the gland in experimental situations
with a greater demand for new endocrine cells.
Pituitary Stem Cells Are Particularly Sensitive to the
Mitogenic Effects of E2 In Vivo
E2 is a strong mitogen in the rodent pituitary, where it induces
proliferation of existing endocrine cells and hormonally null cells
and formation of new lactotrophs inmales (Castrique et al., 2010;
Nolan and Levy, 2006a, 2006b). These could be generated by
division of existing lactotrophs and/or by differentiation frompro-
genitors. In the latter case, maintenance of the pool of progeni-
tors would require compensatory proliferation. We therefore
looked at SOX2-positive cell proliferation after E2 treatment.
Because there are relatively few SOX2-positive cells proliferating
in the adult pituitary (Fauquier et al., 2008), we used BrdU as a
marker and injected it daily for 3 days (Figure 4A).
Three days after the implantation of E2 pellets and daily BrdU
injections, the percentage of BrdU-labeled cells/DAPI nuclei was
more than doubled in treated animals (Figure 4B). We then
compared the proportion of SOX2-positive cells in control and
treated animals. Because we counted cells in fields encompass-426 Cell Stem Cell 13, 419–432, October 3, 2013 ª2013 The Authorsing the cleft, where SOX2-positive cells are the main cell type,
and in the anterior lobe, the proportion of SOX2-positive cells
in both groups is higher (about 8%, see Figure 4C) than observed
in the whole pituitary (2%–3%, data not shown). However, this
proportion is not significantly affected by E2 treatment (Fig-
ure 4C). In contrast, we observed ten times more SOX2;BrdU-
double-positive cells in treated animals (9.75%) than controls
(0.98%) (Figure 4D). The SOX2-positive population is therefore
extremely sensitive to the proliferative effect of E2 within the
anterior lobe population. The vast majority of these cells are
SOX2;SOX9-double-positive: 94% of SOX2;BrdU-double-posi-
tive cells (n = 322 in three treated animals) were also SOX2/
SOX9-double-positive. Such a proliferative effect might be
expected to increase the total proportion of pituitary cells that
are SOX2 positive, and indeed this is slightly elevated in E2-
treated animals (+ 0.92%), but this is not statistically significant
(we would expect, as we see here, a less than 1% increase).
Alternatively the effect on the proportion of SOX2-positive
cells may be slight because once they have divided, a proportion
of the daughter cells may stop expressing the protein, and differ-
entiate or die. It has indeed been suggested that nascent pitui-
tary cells are particularly susceptible to apoptosis (Nolan and
Levy, 2006a). Moreover it has been shown that E2 can elicit an
apoptotic response in the pituitary (for review see Seilicovich,
2010). We therefore quantified apoptosis by performing
active caspase-3 staining, but we did not observe any effect
(Figure 4E).
Therefore, SOX2/SOX9-positive cells proliferate in response to
E2 treatment and are particularly sensitive to its mitogenic effect.
This is in agreement with their proposed function as progenitors.
E2 Effects on Pituitary Stem Cells Are Likely to Be
Indirect
An increase in SOX2-positive cell proliferation in vivo should
result in the formation of more spheres in vitro. To test this
hypothesis, we dissociated pituitaries 3 days after E2 pellet
implantation and seeded them at the same density from treated
and control animals. We obtained a similar number of cells after
dissociation from treated versus sham-operated animals, sug-
gesting that the proliferative effect of E2 is not yet measurable.
In contrast, when we counted spheres after 1 week of culture,
there were significantly more spheres in cultures from treated
animals (Figure 4F, p = 0.0055). To test whether the effects of
E2 on the SOX2-positive cells are direct or indirect, we added
it in vitro on freshly dissociated pituitary cells. In contrast with
the previous experiment, in vitro E2 treatment did not affect pitui-
sphere numbers (Figure 4G, p = 0.38), suggesting that the effect
of E2 on SOX2-positive cells is indirect.
We then looked at the expression of the E2 receptors (ERs),
finding that ERa and ERb are widely expressed in the anterior
lobe, as previously described (Gonza´lez et al., 2008). However,
ER andSOX2 stainingweremutually exclusive (Figure 4H), which
is in agreement with an indirect effect of E2 on sphere-forming
ability and on SOX2-positive cell proliferation.
Pituitary Stem Cells Proliferate after Ablation of a
Pituitary Target Organ
Pituitary target organ ablation, more specifically gonadectomy
and adrenalectomy, induces a transient mitotic wave in the
Figure 4. Estrogen Treatment in Males
Induces Proliferation of Adult SOX2-Positive
Cells In Vivo and Indirectly Induces Forma-
tion of More Pituispheres In Vitro
E2 pellets (0.2 mg) were implanted in 8-week-old
males. BrdU was then injected for 3 days and
pituitaries were harvested.
(A) Double immunofluorescence in a sham and E2-
treated animals for BrdU and SOX2. There is more
BrdU in the E2-treated sample and SOX2;BrdU-
double-positive cells are numerous (arrows).
(B) Percentage of BrdU-positive nuclei in sham
versus treated animals. There is a significant in-
crease of BrdU incorporation in E2-treated animals
(p = 0.003).
(C) The percentage of SOX2-positive cells in the
anterior pituitary is not significantly affected by E2
treatment.
(D) In contrast there is a significant increase in
the percentage of SOX2;BrdU-double-positive/
SOX2+ve cells in E2-treated animals (p = 0.0003).
(E) The percentage of caspase-3-positive cells is
not affected.
(F) In vivo E2 treatment increases significantly the
number of pituispheres obtained after dissociation
(p = 0.006).
(G) In contrast, E2 treatment in vitro, after pituitary
dissociation, does not affect the number of pitui-
sphere formed. E2 effect on SOX2-positive cells is
therefore likely to be indirect.
(H) In agreement with this hypothesis, double
immunofluorescence for SOX2 and ERa/b show
almost exclusive expression patterns in the ante-
rior pituitary.
Scale bars: 50 mm. Data are presented as
mean ± SEM.
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Pituitary Stem Cells Generate Endocrine Cellspituitary followed by new hormonal cells of the appropriate type
to regulate the now ablated organ (gonadotrophs and cortico-
trophs, respectively) (Nolan and Levy, 2006b; Ibrahim et al.,
1986). However, cell division is mainly observed in nonendocrineCell Stem Cell 13, 419–432cells. Moreover, ablation of both gonads
and adrenals does not result in an added
mitotic effect, suggesting that the same
cell population is stimulated by each
treatment. This suggests that a popula-
tion of undifferentiated cells, or progeni-
tors, proliferate in response to organ
ablation and later differentiate (Nolan
and Levy, 2006b).
To ask if these cells include those that
are SOX2 positive, we performed gonad-
ectomies on young males and quantified
proliferation after five daily injections of
BrdU. As previously described (Nolan
and Levy, 2006b), we found a significant
increase in BrdU incorporation/DAPI in
gonadectomized versus sham-operated
animals (Figure 5A), albeit a more modest
one than that induced by E2. As with the
latter, there was a slight, but nonsignifi-
cant, increase in the percentage ofSOX2-positive cells (Figure 5B). In contrast, there are four times
more SOX2;BrdU-double-positive cells/SOX2-positive cells in
gonadectomized compared to sham-operated animals (Fig-
ure 5C). Apoptosis, as assessed by active caspase-3 staining,, October 3, 2013 ª2013 The Authors 427
Figure 5. Pituitary Target Organ Ablation Induces Proliferation of Adult SOX2-Positive Cells In Vivo and Formation of More Pituispheres
In Vitro
Gonadectomies (A–D) and adrenalectomies (E) were performed in 8-week-old males. BrdU was then injected for 5 days and pituitaries were harvested (A–D). (A)
Percentage of BrdU-positive nuclei in sham versus gonadectomized animals. There is a significant increase of BrdU incorporation in gonadectomized animals
(p = 0.02). (B) The percentage of SOX2-positive cells in the anterior pituitary is not significantly affected by the ablation. (C) In contrast there is a significant increase
in the percentage of BrdU;SOX2-double-positive/SOX2+ve cells in gonadectomized animals (p = 0.001). Pituitaries from gonadectomized (D, p = 0.0006) or
adrenalectomized (E, p = 0.005) animals give rise to significantly more spheres in vitro than their sham counterparts. Data are presented as mean ± SEM.
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positive cells are therefore included in the nonendocrine popula-
tion that proliferates in response to organ ablation, in agreement
with their progenitor function.
In order to better characterize this proliferative effect, we per-
formed sphere assay experiments after gonadectomies and
also adrenalectomies. Five days after surgery, pituitaries from
sham-operated and operated animals were dissociated and
cells were plated in sphere-forming conditions. We observed
a significant increase in sphere formation after 1 week of culture
after both gonadectomies (Figure 5D) and adrenalectomies
(Figure 5E).
These data support a progenitor function for the SOX2;SOX9-
double-positive cells. However, the increase in the percentage of
SOX2;BrdU-double-positive cells does not by itself account for
the global increase of BrdU incorporation, here and also after
E2 treatment. After gonadectomies, 12.3% of the BrdU-positive
cells are SOX2;BrdU-double positive compared to 4.5% in
sham-operated animals. Therefore, while significantly account-
ing for the increase in BrdU incorporation, the SOX2+ve popula-
tion is not the only one proliferating in response to organ ablation.
The same is true for the E2 experiment; however, it is well known
that E2 broadly stimulates proliferation of pituitary cells (Castri-
que et al., 2010; Nolan and Levy, 2009). Gonadotrophs and cor-
ticotrophs have also been shown to proliferate after target organ
ablation, although at a rate much lower than that of the SOX2-
positive cells (our observations and Nolan and Levy, 2006b).
It is possible that other classes of differentiated cells are stim-
ulated by E2 and organ ablation. However, the immediate
differentiating progeny of the stem cells, which will be
SOX2ve;SOX9ve, could also account for a significant propor-428 Cell Stem Cell 13, 419–432, October 3, 2013 ª2013 The Authorstion of BrdU-labeled cells: an additional 12% if they do not divide
at all, but all of them if they each divide just three times.
Pituitary Stem Cells Give Rise to New Endocrine Cells
after Target Organ Ablation and E2 Treatment
Wenext decided to use an organ ablation protocol in conjunction
with lineage tracing in order to examine the differentiation poten-
tial of the SOX2+ve, SOX9+ve progenitors in the adult. We chose
adrenalectomies versus gonadectomies because new cortico-
trophs appear rapidly within 1 week after surgery, whereas the
effects of castration on gonadotroph cell number occur later
(Nolan and Levy, 2006b; Ibrahim et al., 1986).
We treated 8-week-old Sox9ires-CreERT2/+;R26REYFP/+ animals
with tamoxifen for 5 consecutive days and performed adrenalec-
tomies the following day. Pituitaries were harvested 6 days after
surgery. We counted 23% more ACTH+ve cells/surface area in
adrenalectomized versus sham-operated samples (Figure 6A
and Figure S4; both groups are tamoxifen treated), in agreement
with previous studies (Nolan and Levy, 2006b; Subburaju and
Aguilera, 2007). The majority of EYFP+ve cells still retain
SOX9 expression (data not shown), but when we counted
EYFP;ACTH-double-positive cells, we observed a significant in-
crease (Figure 6B, p = 0.0001) in the number of double-positive
cells in adrenalectomized versus sham-operated animals
(Figure 6B). To ensure that this effect was specific, we examined
thyrotrophs, because these should not be affected by adrenalec-
tomies. No EYFP;TSH-double-positive cells were observed (n =
2, in one sham and one adrenalectomized animal).
We then estimated the proportion of new corticotrophs,
generated after adrenalectomies, which originate from differen-
tiation of SOX9+ve progenitors. We find that SOX9+ve stem cells
Figure 6. Pituitary Target Organ Ablation Induces Differentiation of Adult SOX9-Positive Stem Cells
Adrenalectomies were performed 24 hr after the last tamoxifen administration (5 mg/25 g/day for 5 days). Pituitaries were harvested 1 week later.
(A) ACTH-positive corticotrophs were counted on two sections/animal and the surface area of the sections was measured. We observed significantly more
corticotrophs after adrenal ablation (p = 0.023).
(B) We almost exclusively observe EYFP;ACTH-double-positive corticotrophs after adrenalectomies in Sox9ires-CreERT2/+;R26REYFP/+ animals (adrenalectomy
n = 5, 2 females and 3 males, sham-operated n = 5, 3 females and 2 males, p = 0.0005, with no difference found between males and females).
(C) Double immunofluorescence illustrating the differentiation of EYFP+ve SOX9 progenitors in ACTH+ve corticotrophs in a Sox9ires-CreERT2/+;R26REYFP/+ animal
after adrenalectomy. Scale bar: 10 mm.
(D) Proportion of new corticotrophs generated from SOX9+ve progenitors. We first assessed the efficiency of SOX9-IRES-CreERT2 by counting the number of
EYFP;SOX9-double-positive cells 48 hr after 5 days of tamoxifen treatment. Eighteen percent (SD = 3.2, n = 3) of SOX9+ve cells were EYFP+ve. We thenmeasured
the surface area of all the sections where we counted ACTH;EYFP-double-positive cells in adrenalectomized animals (n = 5). We corrected this number so that it
represented 100% and not just the 18% of cells generated from SOX9+ve cells. This amounted to 21 corticotrophs/mm2, representing 19% of the new corti-
cotrophs. Data are presented as mean ± SEM.
See also Figure S4 and Table S1.
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generated corticotrophs (Figure 6D and Table S1). The remaining
81% are presumed to arise from division of existing cortico-
trophs (10% of the corticotrophs dividing once would be suffi-
cient) and/or differentiation of SOX9ve committed progenitors.
Finally, we performed lineage tracing experiments after E2
treatment in Sox9ires-CreERT2/+;R26REYFP/+ males. E2 effects on
endocrine cell proliferation and numbers in males are relatively
nonspecific within the different endocrine populations, with
maybe a slightly higher sensitivity of lactotrophs (Castrique
et al., 2010; A. Levy, personal communication) but we observed,
in responding animals, prominent differentiation of the stem cells
in the main anterior lobe endocrine population, GH+ve somato-
trophs (Figure S4).
In conclusion, SOX2- or SOX9-expressing adult pituitary stem
cells can differentiate in response to pharmacological E2 treat-
ment and, more importantly, to physiological demand, whereCethey make a significant contribution to the number of new cells
generated after target organ ablation.
DISCUSSION
In this study, we first demonstrated that SOX2+ve, and also
SOX9+ve cells, are the pituisphere-forming cells. We then
showed, using genetic lineage tracing tools, that both embryonic
and adult SOX2- and SOX9-positive cells give rise to pituitary
endocrine cells, proving that they are progenitors. We previously
hypothesized that SOX2+ve;SOX9ve cells represented stem
cells while SOX2;SOX9-double-positive cells were likely to be
shorter lived, more committed transit amplifying progenitors
(Fauquier et al., 2008). In this present study, we show that, in
fact, SOX9+ve cells maintained their identity in long-term lineage
tracing experiments. The vast majority of these cells are also
SOX2+ve, and therefore SOX2;SOX9-double-positive cells, orll Stem Cell 13, 419–432, October 3, 2013 ª2013 The Authors 429
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Grompe, 2012). Furthermore, to explore the regenerative
potential of these adult stem cells, we analyzed their proliferative
response to two different protocols, E2 administration in males
(Nolan and Levy, 2009) and target organ ablation (Nolan and
Levy, 2006b), both suggested to stimulate proliferation of pitui-
tary progenitors and generation of new endocrine cells (for
review see Rizzoti, 2010). We have shown that both treatments
dramatically increase proliferation of the SOX2;SOX9-double-
positive cells and, in conjunction with genetic lineage tracing,
we demonstrate that they can give rise to new endocrine cells
of the appropriate type in response to target organ ablation,
while E2 treatment in males induced differentiation predomi-
nantly into somatotrophs.
In the embryo, in agreement with endocrine cell birth-dating
experiments (Davis et al., 2011), SOX2+ve cells give rise to
more hormone cells before 14.5 dpc, at which stage SOX9 is
upregulated. SOX9 expression is therefore associated with a
decreased differentiation rate. This suggests that SOX9 expres-
sion correlates with a switch of SOX2+ve cell identity from a highly
proliferative differentiative progenitor to a more quiescent
stem cell.
Postnatally, the tamoxifen effect on gonadotroph cell numbers
prevents us frommaking any conclusion about the normal phys-
iological participation of progenitors in this phase of pituitary
growth. They can clearly give rise to all endocrine lineages, so
they are recruited to build the mature gland. However, the pro-
portion of progenitors giving rise to gonadotrophs (about 35%)
seems quite large in view of the slight increase in LH+ve cell
numbers (31.2). Moreover, in adults, where tamoxifen does
not have such an impact, stem cells mainly retain their identity,
except when an additional stimulus, such as adrenalectomy,
instructs them to differentiate. Therefore postnatal pituitary
stem cells are mainly mobilized in specific or exceptional situa-
tions to generate new endocrine cells.
SOX2-CreERT2 and SOX9-IRES-CreERT2 postnatal lineage
tracing results suggest that there are differences between
both cell lineages despite the fact that more than 95% of
the cells are double positive. In addition, we suspect that
the difference in efficiency between both tools may affect
lineage tracing results. With a less efficient tool, such as
Sox9ires-CreERT2, we see far fewer recombined cells and this
could (in proportion) favor the presence, in the EYFP+ve popu-
lation, of more long-lived stem cells than shorter-lived differen-
tiated progeny.
Hormone deficiencies, congenital or acquired, can be
managed by replacement or substitution therapies. However
physiological secretion patterns cannot be mimicked by these
treatments and it would be better to restore missing endocrine
cells (for review see Castinetti et al., 2011). Here we have been
able to stimulate proliferation and differentiation of stem cells
into new somatotrophs after E2 treatment in males and, in
response to adrenal ablation, into corticotrophs, within 1 week
after surgery. More precisely, after adrenalectomies, differentia-
tion from adult progenitors provided a significant proportion
(19%) of the new corticotrophs. It is now important to investigate
the physiological mechanisms instructing the stem cells to differ-
entiate and integrate into the appropriate hormonal cell network
(for review see Mollard et al., 2012), to be able to manipulate430 Cell Stem Cell 13, 419–432, October 3, 2013 ª2013 The Authorsthese in regenerative medicine, or, for example, to control
aspects of reproductive function.
In conclusion, we have been able to show that in the pituitary,
an organ where cell turnover is low and differentiated endocrine
cells can proliferate, adult progenitors can be mobilized and
made to differentiate toward a specific cell fate. The target organ
ablation model we have used here will now allow us to dissect
the mechanisms underlining this stem cell mobilization, in order
to potentially direct new endocrine cell generation, particularly in
pathological situations.
EXPERIMENTAL PROCEDURES
Ethics Statement
All experiments carried out on mice were approved under the UK Animal
(scientific procedures) Act (project license 80/2405).
Mice
Sox9ires-CreERT2/+ (Furuyama et al., 2011) and Sox2CreERT2/+ (Arnold et al., 2011)
mice were bred with R26REYFP/EYFP (Srinivas et al., 2001) mice for lineage
tracing studies. Cre activity was induced by 4-OHT treatments in both preg-
nant females (0.1 to 0.15 mg/g/day) for embryo analysis and in P0/P2 pups
(1 mg) and by tamoxifen treatment in adult (5 mg/25 g/day for 3 to 5 consec-
utive days). CBA/Ca 3 C57BL/10 F1 hybrids, 8–11 weeks old, were used for
estrogen administration and organ ablation experiments. For each experiment
(comprising three experimental and three sham operated animals), animals of
the same age were used. For estrogen treatment, 0.2 mg (as pellets releasing
9.5 mg/day, b-oestradiol 3-benzoate, Innovative Research of America) was
implanted subcutaneously under anesthesia. For gonadectomies and adrenal-
ectomies, bilateral ablation was performed under anesthesia. BrdU (100 mg/g
body weight) was injected daily starting the day after implantation/surgery. For
lineage tracing after adrenalectomies, tamoxifen was administrated for 3 to 5
consecutive days at 5 mg/25 g/day and surgery was performed on day 6.
Pituitaries were harvested 1 week after surgery.
Immunofluorescence
Pituitaries were harvested and fixed by intracardiac perfusion with 4% PFA.
Immunofluorescence was performed on cryosections as described (Rizzoti
et al., 2004) using a goat anti-SOX2 antibody (ISL, 1/500), a goat or rabbit
anti-SOX9 antibody (R&D and a gift from F. Poulat, Montpellier, France,
respectively, 1/300), a rat anti-BrdU antibody (Abcam, 1/200), a rabbit anti-
estrogen receptor antibody (Novus, 1/100), a rat anti-GFP antibody (Nacalai
Tesque, 1/1,000), rabbit anti-Pit-1 (a gift from S. Rhodes, Indianapolis), and
rabbit anti-GH, PRL, LH, and ACTH antibodies (provided by A.F. Parlow,
NHPP, Torrance, USA) followed by anti-goat, rabbit, or rat Alexa 555, 488,
or 647 secondary antibodies (Molecular Probes).
Cell Counting and Statistical Analysis
For lineage tracing analysis, EYFP-positive cells were counted on a minimum
of 10 fields randomly chosen and encompassing the whole pituitary. For estro-
gen treatment and endocrinolectomy, a minimum of 3,000 DAPI-positive
nuclei was counted per animal, on four different fields taken on different
sections (two encompassing the cleft and two in the anterior lobe), using
cell-counting software (Zhu et al., 2010). Within these, the numbers of
SOX2-positive, BrdU-positive, and SOX2;BrdU-double-positive cells were
counted blindly and manually. For lineage tracing after adrenalectomies, pitu-
itaries were sectioned serially on five slides. The number of ACTH/EYFP-dou-
ble-positive cells was counted on one slide/animal and the surface area was
measured using Fiji software. ANOVA tests were performed for statistical anal-
ysis using NCSS software. Angular transformation was applied to compare
percentages.
Pituitary Dissociation for FACS and Sphere Assay
Pituitaries were dissociated as described (Castrique et al., 2010), subject to
FACS for GFP with mice carrying Sox2EGFP (Ellis et al., 2004) or Sox9iresGFP
alleles (Furuyama et al., 2011), and cultured in sphere-forming conditions
Cell Stem Cell
Pituitary Stem Cells Generate Endocrine Cells(Fauquier et al., 2008). To assess sphere-forming efficiency after estrogen
treatment or endocrinolectomy, pituitaries were harvested 3 and 6 days after
surgery, respectively, and spheres were counted blindly and manually after
1 week in culture. To assess the effects of estrogen in vitro, E2 (b-estradiol,
Sigma) was added daily (0.1 ng/ml) and spheres were counted after 1 week
in culture.
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